2016 was another record year of biologics sales with antibodies accounting for two-thirds
- Category: Press Room
- Published on Friday, 17 March 2017 13:34
- Hits: 3597
STUTTGART, Germany I March 17, 2017 I Sales of branded originator biologics in 2016 continued to reach a record high of US$ 163 bln, a plus of 5.8% compared with the previous year. Growth drivers were therapeutic antibodies for treatment of cancer and inflammatory diseases, especially the emerging immuno-oncology antibodies and novel anti-inflammatory antibodies different from anti-TNF. Interestingly, sales of all anti-inflammatory antibodies including the anti-TNF family were 63% higher than those of the cancer antibodies. Nearly two-thirds of all biologics sales are attributable to antibodies, while 2016 sales of therapeutic proteins were 10% lower than those in 2015. Nearly all classes of therapeutic proteins except enzyme replacement therapies have seen a decline of sales in 2016.
A total of 42 biologic therapeutics reached blockbuster status with 2016 sales exceeding US$ 1 bln: 25 antibodies and 17 proteins. Eight biologics reached global sales in 2015 of more than US$ 5 bln. Four biologics were new in the blockbuster biologics list, among them the immune checkpoint modulator nivolumab which made it among the TOP 10 blockbuster biologics. Six biopharmaceutical companies posted biologics sales of more than US$ 10 bln in the year 2016.
The report „Blockbuster Biologics 2016: Sales of Recombinant Therapeutic Antibodies & Proteins“ can be acquired at La Merie Publishing’s News Center and Online Store www.PipelineReview.com: https://www.pipelinereview.com/index.php/store-online/blockbuster-biologics-2016-sales-of-recombinant-therapeutic-antibodies-proteins-detail
The report provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2016. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, published currency into US$. Sales figures represent the sum of revenues in all territories where the products were marketed. Growth rates usually are listed as reported (in some cases on constant exchange rates).
Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2016 sales higher than US$ 1 bln. Another ranking list was prepared for companies according to biologics sales in 2016 and the percentage of antibody sales vs protein sales.
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing